NCT00519324 - Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

January 31, 2009

Conditions

Advanced Gastric Cancer

Interventions

DRUG

Everolimus

10 mg/day (2 tablets of 5 mg each)

Trial Locations (8)

Novartis investigative Site, Aichi

Novartis investigative Site, Chiba

Novartis investigative Site, Ehime

Novartis Investigative Site, Hokkaido

Novartis investigative Site, Osaka

Novartis investigative Site, Shizuoka

Novartis Investigative Site, Tochigi

Novartis investigative Site, Tokyo